The new anti-viral agent Sofosbuvir taken either before or after liver transplant reduces hepatitis C recurrence as reported via aidsmap.
An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly
two-thirds of cases as recently reported at the AASLD meeting.
Sofosbuvir is just one of a number of new anti-viral oral agents that are being trialled for the treatment of hepatitis C (as pictured in the graphic). Hence this is an encouraging report.
The combination of Sofosbuvir with a different anti-viral agent Ledipasvir is reported via the Guardian (post publication in The Lancet )-